HIGHLIGHTS
SUMMARY
Triple-negative breast cancer (TNBC) is negative for hormone_receptors and human epidermal growth factor receptor 2 (HER2). For patients with stage I TNBC, the HER2-low population had a significantly worse prognosis than the HER2-0 population. Breast cancer is divided into subtypes depending on hormone_receptor (estrogen receptor and progesterone receptor ) and human epidermal growth factor receptor 2 (HER2) expression. As TNBC is defined as both hormone_receptor-negative and HER2 negative, neither hormone therapy nor HER2 targeted therapy can be applied, and chemotherapies are the main treatments. HER2-low expression, defined as HER2 1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.